| scholarly article | Q13442814 |
| P2093 | author name string | Amos B. Smith | |
| Carlo Ballatore | |||
| John Q. Trojanowski | |||
| Kurt R. Brunden | |||
| Virginia M.-Y. Lee | |||
| P2860 | cites work | Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau | Q24294296 |
| Repeat motifs of tau bind to the insides of microtubules in the absence of taxol | Q24540276 | ||
| Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease | Q24596763 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model | Q28115206 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| Differential regulation of dynein and kinesin motor proteins by tau | Q28589618 | ||
| Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease | Q28910345 | ||
| Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease | Q29617286 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Tau-mediated neurodegeneration in Alzheimer's disease and related disorders | Q29618148 | ||
| Neurodegenerative tauopathies | Q29619895 | ||
| Multiple-motor based transport and its regulation by Tau. | Q30478710 | ||
| Pseudophosphorylation and glycation of tau protein enhance but do not trigger fibrillization in vitro | Q31111749 | ||
| Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model | Q33715257 | ||
| Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies | Q34211969 | ||
| Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy | Q34218584 | ||
| Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly | Q34275737 | ||
| Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. | Q34324670 | ||
| The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies | Q34587678 | ||
| Novel microtubule-targeting agents - the epothilones. | Q34611212 | ||
| Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. | Q34722347 | ||
| Differential regulation of microtubule dynamics by three- and four-repeat tau: implications for the onset of neurodegenerative disease | Q35234889 | ||
| Microtubule Reduction in Alzheimer's Disease and Aging Is Independent of τ Filament Formation | Q35749171 | ||
| The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice | Q35875920 | ||
| Biochemistry and molecular biology of tauopathies | Q36642466 | ||
| Targeting the microtubules in breast cancer beyond taxanes: the epothilones | Q36779179 | ||
| Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments | Q37238270 | ||
| Design, synthesis, and biological evaluation of new-generation taxoids | Q37325768 | ||
| Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. | Q37361338 | ||
| Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation | Q38357011 | ||
| Microtubule stabilizing drugs for the treatment of Alzheimer's disease | Q40496709 | ||
| Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization | Q41236012 | ||
| Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress | Q41830251 | ||
| Paclitaxel C-10 carbamates: potential candidates for the treatment of neurodegenerative tauopathies | Q41998110 | ||
| Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments | Q44812655 | ||
| Tau interaction with microtubules in vivo | Q45163054 | ||
| Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ | Q45249730 | ||
| Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation | Q47602087 | ||
| Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo | Q48134444 | ||
| Structure and novel exons of the human tau gene | Q48149325 | ||
| Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding | Q48277664 | ||
| Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. | Q48338403 | ||
| Regions with abundant neurofibrillary pathology in human brain exhibit a selective reduction in levels of binding-competent tau and accumulation of abnormal tau-isoforms (A68 proteins) | Q48532140 | ||
| Characterization of tau pathologies in gray and white matter of Guam parkinsonism-dementia complex | Q48586971 | ||
| Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons. | Q48654126 | ||
| Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease | Q48820847 | ||
| Plaques, tangles and dementia. A quantitative study | Q48874775 | ||
| Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease | Q48934697 | ||
| Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. | Q52200995 | ||
| Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. | Q52221648 | ||
| Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform | Q54965151 | ||
| A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease | Q58202813 | ||
| Domains of tau protein and interactions with microtubules | Q72146653 | ||
| Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel | Q80585219 | ||
| Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage | Q94526211 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain | Q1073 |
| tauopathy | Q2397106 | ||
| microtubule | Q189933 | ||
| P304 | page(s) | 661-6 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | Biochemical Society Transactions | Q864226 |
| P1476 | title | Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies | |
| P478 | volume | 40 |
| Q26752846 | A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer |
| Q38534263 | Are there treatments for atypical parkinsonism? An update on actual options |
| Q38957250 | Axonal pathology in Krabbe's disease: The cytoskeleton as an emerging therapeutic target |
| Q38232821 | Axonal transport defects in Alzheimer's disease |
| Q36852550 | Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies |
| Q38223118 | Clinical trials: past, current, and future for atypical Parkinsonian syndromes |
| Q50566064 | Combination of PKCε Activation and PTP1B Inhibition Effectively Suppresses Aβ-Induced GSK-3β Activation and Tau Phosphorylation. |
| Q36898998 | Direct modulation of microtubule stability contributes to anthracene general anesthesia |
| Q41240654 | Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy |
| Q53397873 | Interaction between a MAPT variant causing frontotemporal dementia and mutant APP affects axonal transport. |
| Q36934113 | MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease |
| Q47240527 | Microfluidic platforms for the study of neuronal injury in vitro. |
| Q38307155 | Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and Disease. |
| Q92782695 | Microtubules: A Key to Understand and Correct Neuronal Defects in CDKL5 Deficiency Disorder? |
| Q92761855 | Neuroprotective Approach of Anti-Cancer Microtubule Stabilizers Against Tauopathy Associated Dementia: Current Status of Clinical and Preclinical Findings |
| Q38162441 | Notch signalling in adult neurons: a potential target for microtubule stabilization. |
| Q99631302 | Postnatal Role of the Cytoskeleton in Adult Epileptogenesis |
| Q35103703 | Rescue of tau-induced synaptic transmission pathology by paclitaxel |
| Q37449999 | Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer's disease |
| Q40354154 | Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy. |
| Q36968220 | The importance of tau phosphorylation for neurodegenerative diseases |
Search more.